目的 探究脑血栓片联合依达拉奉注射液治疗急性脑梗死的临床疗效。方法 选取2013年1月-2016年12月于宝丰县人民医院收治的急性脑梗死患者98例为研究对象，所有患者按随机数字表法分为对照组和治疗组，每组各49例。对照组静脉滴注依达拉奉注射液，30 mg加入0.9%氯化钠注射液100 mL中，30 min内滴完，2次/d。治疗组在对照组治疗的基础上口服脑血栓片，2片/次，3次/d。两组患者均连续治疗14 d。观察两组的临床疗效，比较两组美国国立卫生研究院卒中量表（NIHSS）评分、氧化应激因子水平和炎症因子水平。结果 治疗后，对照组、治疗组总有效率分别为77.55%、91.84%，两组总有效率比较差异具有统计学意义（P<0.05）。治疗7、14 d后，两组NIHSS评分均明显下降（P<0.05），同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组NIHSS评分显著低于同期对照组，两组比较差异具有统计学意义（P<0.05）。治疗7、14 d后，两组血清丙二醛（MDA）水平明显降低，一氧化氮（NO）、超氧化物歧化酶（SOD）水平明显升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组血清氧化应激因子水平明显优于同期对照组，两组比较差异具有统计学意义（P<0.05）。治疗7、14 d后，两组血清肿瘤坏死因子（TNF-α）、白介素（IL）-6、IL-10、超敏C反应蛋白（hs-CRP）水平明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组炎症因子水平均明显低于同期对照组，两组比较差异具有统计学意义（P<0.05）。结论 脑血栓片联合依达拉奉注射液治疗急性脑梗死患者，能有效改善机体内炎症反应和氧化应激水平，促进神经功能恢复，且安全性良好，具有一定的临床推广应用价值。

Objective To investigate the effect of Naoxueshuan Tablets combined with Edaravone Injection in treatment of acute cerebral infarction. Methods Patients (98 cases) with acute cerebral infarction in People's Hospital of Baofeng from January 2013 to December 2016 were randomly divided into control group and treatment group, and each group had 49 cases. Patients in the control group were iv administered with Edaravone Injection, 30 mg Edaravone Injection added into 100 mL 0.9% NaCl injection, twice daily. Patients in the treatment group were po administered with Naoxueshuan Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and NIHSS scores, serum levels of oxidative stress factors, and serum levels of inflammatory factors in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 77.55% and 91.84%, respectively, and there were no differences between two groups. After treatment for 7 and 14 d, NIHSS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And NIHSS scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment for 7 and 14 d, MDA levels in two groups were significantly decreased, but NO and SOD levels were significantly increased, and there were differences in the same group (P<0.05). And serum levels of oxidative stress factors in the treatment group were significantly better than those in the control group in the same period, with significant difference between two groups (P<0.05). After treatment for 7 and 14 d, serum levels of TNF-α, IL-6, hs-CRP in two groups were significantly decreased, and there were differences in the same group (P<0.05). And serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group in the same period, with significant difference between two groups (P<0.05). Conclusion Naoxueshuan Tablets combined with Edaravone Injection has good efficacy in treatment of acute cerebral infarction, and can effectively reduce the level of oxidative stress and inflammatory response, which is conducive to nerve recovery, which has a certain clinical application value.